

Table S1 The detailed clinical and pathological features of study population

Clinicopathological variables	Number (total =106)	Percentage (%)
Age (years)		
≤50	37	34.9
>50	69	65.1
Tumor size (cm)		
<5	89	84.0
≥5	17	16.0
Grade		
I	14	13.2
II	35	33.0
III	57	53.8
Molecular subtype		
Luminal A	32	30.2
Luminal B	55	51.9
HER2 positive	5	4.7
Basl-like	14	13.2
Lymph metastasis		
Yes	25	23.6
No	81	76.4
TNM classification		
I	10	9.4
II	49	46.2
III	30	28.3
IV	17	16.1
Status		
Alive	52	49.1
Dead	28	26.4
Lost to follow up	26	24.5

HER2, human epidermal growth factor receptor 2; TNM, tumor-node-metastasis.

Table S2 The detailed clinical and pathologic characteristics of study population in the downloaded TCGA database

Characteristics	Low expression of PLEKHA4	High expression of PLEKHA4
Total, n	543	544
Age (years), n (%)		
≤60	278 (25.6)	325 (29.9)
>60	265 (24.4)	219 (20.1)
Pathologic T stage, n (%)		
T1	131 (12.1)	147 (13.6)
T2	321 (29.6)	310 (28.6)
T3	65 (6.0)	75 (6.9)
T4	23 (2.1)	12 (1.1)
Pathologic N stage, n (%)		
N0	249 (23.3)	267 (25.0)
N1	184 (17.2)	175 (16.4)
N2	64 (6.0)	52 (4.9)
N3	35 (3.3)	42 (3.9)
Pathologic M stage, n (%)		
M0	468 (50.6)	437 (47.2)
M1	14 (1.5)	6 (0.6)
Pathologic stage, n (%)		
Stage I	87 (8.2)	95 (8.9)
Stage II	307 (28.9)	312 (29.4)
Stage III	123 (11.6)	121 (11.4)
Stage IV	12 (1.1)	6 (0.6)
Histological type, n (%)		
Infiltrating ductal carcinoma	434 (44.2)	342 (34.9)
Infiltrating lobular carcinoma	55 (5.6)	150 (15.3)
ER status, n (%)		
Negative	130 (12.5)	110 (10.6)
Indeterminate	2 (0.2)	0 (0.0)
Positive	381 (36.7)	416 (40.0)
PR status, n (%)		
Negative	199 (19.2)	143 (13.8)
Indeterminate	2 (0.2)	2 (0.2)
Positive	311 (30.0)	381 (36.7)
HER2 status, n (%)		
Negative	261 (35.8)	299 (41.0)
Indeterminate	7 (1.0)	5 (0.7)
Positive	104 (14.3)	53 (7.3)

Table S2 (continued)

Table S2 (continued)

Characteristics	Low expression of PLEKHA4	High expression of PLEKHA4
Menopause status, n (%)		
Pre	109 (11.2)	121 (12.4)
Peri	17 (1.7)	23 (2.4)
Post	369 (37.8)	337 (34.5)
OS event, n (%)		
Alive	451 (41.5)	484 (44.5)
Dead	92 (8.5)	60 (5.5)
DSS event, n (%)		
No	478 (44.8)	504 (47.2)
Yes	53 (5.0)	32 (3.0)
PFI event, n (%)		
No	456 (42.0)	484 (44.5)
Yes	87 (8.0)	60 (5.5)
Race, n (%)		
Asian	33 (3.3)	27 (2.7)
Black or African American	83 (8.3)	99 (9.9)
White	367 (36.8)	388 (38.9)
Radiation therapy, n (%)		
No	222 (22.5)	212 (21.5)
Yes	258 (26.1)	295 (29.9)

TCGA, The Cancer Genome Atlas; PLEKHA4, pleckstrin homology containing family A, number 4; T, tumor; N, lymph nodes; M, metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; DSS, disease-specific survival; PFI, progression-free interval.